TIL Stock Price, Instil Bio, Inc. Quote, Chart

Market Summary

USD11.79-0.01

Delayed

-0.08%

TIL Stock Price

View Fullscreen

TIL RSI Chart

TIL Valuation

Market Cap

76.7M

Price/Earnings (Trailing)

-0.62

Price/Sales (Trailing)

8.66

EV/EBITDA

-0.49

Price/Free Cashflow

-1.04

TIL Price/Sales (Trailing)

TIL Profitability

EBT Margin

-1762.30%

Return on Equity

-59.91%

Return on Assets

-40.26%

Free Cashflow Yield

-96.44%

TIL Fundamentals

TIL Revenue

Revenue (TTM)

8.9M

Rev. Growth (Yr)

22.22%

Rev. Growth (Qtr)

-5.1%

TIL Earnings

Earnings (TTM)

-123.3M

Earnings Growth (Yr)

57.42%

Earnings Growth (Qtr)

-88.02%

Breaking Down TIL Revenue

Last 7 days

1.8%

Last 30 days

11.3%

Last 90 days

0.3%

Trailing 12 Months

1874.2%

How does TIL drawdown profile look like?

TIL Financial Health

Current Ratio

14.19

TIL Investor Care

Buy Backs (1Y)

95.00%

Diluted EPS (TTM)

-27.3

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	8.9M	0	0	0
2023	5.6M	7.4M	8.5M	8.9M
2022	169.0K	640.0K	1.9M	3.7M
2021	0	109.0K	89.0K	72.0K
2020	0	0	0	138.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Instil Bio, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 15, 2022	mcgaughy r kent jr	sold	-	-	-260,323	-
Mar 23, 2021	mcgaughy r kent jr	acquired	-	-	8,028,790	-
Mar 23, 2021	mcgaughy r kent jr	bought	9,000,000	20.00	450,000	-
Mar 23, 2021	nielsen jack	acquired	-	-	12,186,800	-
Mar 23, 2021	nielsen jack	bought	6,000,000	20.00	300,000	-
Mar 23, 2021	shah nimish p	bought	6,000,000	20.00	300,000	-
Mar 23, 2021	shah nimish p	acquired	-	-	6,565,080	-
Mar 23, 2021	vivo capital ix, llc	acquired	-	-	12,186,800	-
Mar 23, 2021	vivo capital ix, llc	bought	6,000,000	20.00	300,000	-
Mar 23, 2021	curative ventures v llc	bought	9,000,000	20.00	450,000	-

Which funds bought or sold TIL recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	STATE STREET CORP	reduced	-7.15	30,291	126,166	-%
May 15, 2024	CITADEL ADVISORS LLC	reduced	-45.44	-48,900	166,730	-%
May 15, 2024	Royal Bank of Canada	sold off	-100	-1,000	-	-%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	reduced	-12.6	92,424	479,520	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	reduced	-36.91	-40,081	338,915	-%
May 15, 2024	MARSHALL WACE, LLP	unchanged	-	192,790	654,760	-%
May 15, 2024	CPMG Inc	reduced	-	1,306,720	4,437,960	1.61%
May 15, 2024	Nantahala Capital Management, LLC	reduced	-50.00	-565,176	1,374,750	0.08%
May 15, 2024	TWO SIGMA ADVISERS, LP	reduced	-19.84	38,149	318,481	-%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-14.91	505	2,959	-%

Are Funds Buying or Selling TIL?

Are funds buying TIL calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own TIL

No. of Funds

Unveiling Instil Bio, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 02, 2024	bml investment partners, l.p.	5.3%	346,190	SC 13G
Apr 10, 2023	fmr llc	-	0	SC 13G/A
Feb 14, 2023	ra capital management, l.p.	0%	0	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Jun 22, 2022	ra capital management, l.p.	5.93%	7,670,793	SC 13G
Feb 09, 2022	fmr llc	-	0	SC 13G/A

Recent SEC filings of Instil Bio, Inc.

View All Filings

Date Filed	Form Type	Document
May 10, 2024	8-K	Current Report
May 10, 2024	10-Q	Quarterly Report
Apr 26, 2024	DEFA14A	DEFA14A
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	ARS	ARS
Apr 26, 2024	8-K	Current Report
Apr 02, 2024	SC 13G	Major Ownership Report
Mar 21, 2024	S-8	Employee Benefits Plan
Mar 21, 2024	8-K	Current Report
Mar 21, 2024	10-K	Annual Report

Peers (Alternatives to Instil Bio, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Instil Bio, Inc. News

Latest updates

Instil Bio, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4	2020Q3	2020Q2	2020Q1
Revenue	-6.1%	2,062,000	2,195,000	2,313,000	2,287,000	2,071,000	1,796,000	1,276,000	486,000	97,000	35,000	22,000	15,000	-	52,000	42,000	44,000
Operating Expenses	84.0%	23,955,000	13,020,000	66,716,000	20,987,000	58,446,000	56,799,000	56,649,000	58,724,000	54,286,000	53,752,000	43,024,000	35,381,000	17,477,000	7,763,000	4,635,000	3,907,000
S&GA Expenses	-100.0%	-	10,872,000	11,941,000	11,518,000	13,222,000	12,910,000	16,989,000	17,224,000	15,112,000	11,175,000	13,960,000	14,195,000	7,230,000	2,855,000	2,398,000	1,900,000
R&D Expenses	265.9%	7,256,000	1,983,000	8,492,000	8,459,000	20,670,000	20,722,000	39,660,000	41,500,000	39,174,000	42,577,000	29,064,000	21,186,000	10,247,000	4,908,000	2,237,000	2,007,000
EBITDA Margin	0.3%	-16.43	-16.48	-22.18	-23.85	-38.79	-59.47	-116	-325	-1,093	-2,138	-	-	-	-	-	-
Interest Expenses	0.1%	1,981,000	1,980,000	2,003,000	590,000	636,000	745,000	807,000	331,000	-	-	-	-	-	-	-	-
Income Taxes	-	-	-	-	-	-	-605,000	-371,000	-609,000	-488,000	1,060,000	-658,000	-159,000	151,000	-	-	-
Earnings Before Taxes	100.0%	-	-12,925,000	-67,432,000	-18,662,000	-57,068,000	-54,449,000	-56,595,000	-59,601,000	-54,605,000	-54,290,000	-43,663,000	-35,470,000	-17,034,000	-7,262,000	-9,202,000	-4,089,000
EBT Margin	-0.1%	-17.62	-17.61	-23.34	-25.14	-40.45	-61.63	-118	-331	-1,112	-2,177	-1,342	-762	-272	-	-	-
Net Income	-88.0%	-24,302,000	-12,925,000	-67,432,000	-18,662,000	-57,068,000	-53,844,000	-56,224,000	-58,992,000	-54,117,000	-55,350,000	-43,005,000	-35,311,000	-17,185,000	-7,262,000	-9,202,000	-4,089,000
Net Income Margin	20.9%	-13.92	-17.61	-23.27	-25.01	-40.17	-61.06	-118	-330	-1,111	-2,177	-1,332	-760	-273	-	-	-
Free Cashflow	-7.1%	-14,392,000	-13,439,000	-19,584,000	-26,540,000	-43,129,000	-49,988,000	-66,076,000	-73,403,000	-75,286,000	-61,254,000	-51,140,000	-40,717,000	-21,125,000	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet														(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Assets	-5.9%	306	326	340	408	427	482	533	569	565	610	647	673	696	319
Current Assets	0.2%	161	161	196	221	240	269	314	368	391	464	523	574	614	246
Cash Equivalents	-40.4%	5.00	9.00	9.00	22.00	27.00	44.00	42.00	43.00	62.00	38.00	21.00	567	610	242
Net PPE	-3.4%	134	139	139	181	180	197	185	167	141	122	104	79.00	63.00	55.00
Goodwill	-	-	-	-	-	-	-	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00
Liabilities	0.7%	100	100	106	112	116	119	122	110	56.00	55.00	46.00	37.00	31.00	27.00
Current Liabilities	7.5%	11.00	11.00	13.00	18.00	27.00	33.00	42.00	43.00	37.00	41.00	32.00	24.00	17.00	13.00
Shareholder's Equity	-8.9%	206	226	234	297	311	364	411	458	509	555	601	635	665	-
Retained Earnings	-4.2%	-605	-580	-568	-500	-481	-424	-371	-314	-255	-201	-146	-103	-68.05	-44.92
Additional Paid-In Capital	0.6%	812	807	803	798	794	789	782	774	765	757	748	739	733	6.00
Shares Outstanding	0%	7.00	7.00	130	130	130	-	129	129	129	129	129	82.00	35.00	-
Float	-	-	-	-	34.00	-	-	-	286	-	-	-	1,071	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																	(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1
Cashflow From Operations	-7.6%	-14,392	-13,381	-14,426	-19,560	-34,662	-36,976	-40,877	-47,260	-55,051	-42,790	-29,395	-32,224	-17,729	-16,823	-7,235	-3,276	-2,282
Share Based Compensation	-0.8%	4,515	4,553	4,670	4,413	4,530	6,643	7,982	8,323	7,493	8,904	8,736	5,745	2,812	415	330	899	62.00
Cashflow From Investing	-33.7%	9,243	13,950	2,319	10,331	14,528	32,802	25,373	-21,501	77,867	59,958	-516,732	-8,493	-9,129	-45,271	-4,302	-275	-1,274
Cashflow From Financing	-	-	-	-587	4,202	4,467	6,202	14,722	50,624	338	198	121	-1,860	394,705	133,071	114	179,863	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

TIL Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 7,256	$ 20,670
General and administrative	12,424	13,222
Restructuring and impairment charges	4,275	24,554
Total operating expenses	23,955	58,446
Loss from operations	(23,955)	(58,446)
Interest income	2,062	2,071
Interest expense	(1,981)	(636)
Other expense, net	(428)	(57)
Net loss	(24,302)	(57,068)
Other comprehensive income (loss):
Foreign currency translation	44	(230)
Unrealized (loss) gain on available-for-sale securities, net	(259)	317
Total comprehensive loss	$ (24,517)	$ (56,981)
Net loss per share, basic (in dollars per share)	$ (3.74)	$ (8.77)
Net loss per share, diluted (in dollars per share)	$ (3.74)	$ (8.77)
Weighted-average shares used in computing net loss per share, basic (in shares)	6,503,913	6,503,913
Weighted-average shares used in computing net loss per share, diluted (in shares)	6,503,913	6,503,913

TIL Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 5,484	$ 9,195
Restricted cash	0	1,501
Marketable securities	148,304	141,161
Prepaid expenses and other current assets	6,325	8,902
Held for sale assets	918	0
Total current assets	161,031	160,759
Property, plant and equipment, net	133,903	138,684
Operating lease right-of-use assets	1,935	2,387
Long-term investments	7,666	23,161
Other long-term assets	1,768	639
Total assets	306,303	325,630
Current liabilities:
Accounts payable	1,225	1,212
Accrued expenses and other current liabilities	10,126	9,347
Total current liabilities	11,351	10,559
Contingent consideration, net of current portion	4,955	4,858
Operating lease liabilities, non-current	2,451	2,877
Loan payable	81,676	81,427
Other long-term liabilities	43	80
Total liabilities	100,476	99,801
Commitments and contingencies (Note 6)
Stockholders’ equity:
Preferred stock, par value $0.000001 per share; 10,000,000 shares authorized; zero shares issued and outstanding as of March 31, 2024, and December 31, 2023	0	0
Common stock, par value $0.000001 per share; 300,000,000 shares authorized; 6,503,913 shares issued and outstanding as of March 31, 2024, and December 31, 2023	0	0
Additional paid-in capital	811,673	807,158
Accumulated other comprehensive loss	(563)	(348)
Accumulated deficit	(605,283)	(580,981)
Total stockholders’ equity	205,827	225,829
Total liabilities and stockholders’ equity	$ 306,303	$ 325,630

About Instil Bio, Inc.

Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its lead product is ITIL-306, a Co-Stimulatory Antigen Receptor molecule to recognize folate receptor alpha, a tumor-associated antigen that is expressed on various solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer. The company was incorporated in 2018 and is headquartered in Dallas, Texas.

CEO	Mr. Bronson Crouch
WEBSITE	https://instilbio.com
INDUSTRY	Biotechnology
EMPLOYEES	192

Instil Bio, Inc. Frequently Asked Questions

What is the ticker symbol for Instil Bio, Inc.? What does TIL stand for in stocks?

TIL is the stock ticker symbol of Instil Bio, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Instil Bio, Inc. (TIL)?

As of Fri May 17 2024, market cap of Instil Bio, Inc. is 76.68 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TIL stock?

You can check TIL's fair value in chart for subscribers.

What is the fair value of TIL stock?

You can check TIL's fair value in chart for subscribers. The fair value of Instil Bio, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Instil Bio, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TIL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Instil Bio, Inc. a good stock to buy?

The fair value guage provides a quick view whether TIL is over valued or under valued. Whether Instil Bio, Inc. is cheap or expensive depends on the assumptions which impact Instil Bio, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TIL.

What is Instil Bio, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, TIL's PE ratio (Price to Earnings) is -0.62 and Price to Sales (PS) ratio is 8.66. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TIL PE ratio will change depending on the future growth rate expectations of investors.